Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

SHAWN WINDSOR: Detroit Pistons learn mettle tops momentum in Game 3 NBA playoffs loss to New York Knicks After the game, the lead official, Zach Zarba, told the pool reporter (the Freep's Omari ...